Search for: [Abstract = "Gamma\-aminobutyric acid \(GABA\) and glycine are two primary inhibitory neurotransmitters in the central nervous system \(CNS\). In addition, glycine influences the activity of the glutamatergic system by acting as a co\-agonist of the NMDA receptor. One of the main regulators of GABA and glycine concentration in the CNS are the membrane transporters belonging to the SLC6 family. There are 4 types of GABA transporters\: GAT\-1, BGT\-1, GAT\-2, GAT\-3\; and two main types of glycine transporters\: GlyT\-1, GlyT\-2. Studies indicate that blocking GABA and glycine reuptake may be beneficial in the treatment of many disorders, including epilepsy, anxiety, depression, neuropathic pain, schizophrenia, and Alzheimer's disease. Although the potential for the use of GABA and glycine transporter inhibitors appears to be high, the only drug approved for treatment to date is tiagabine, a selective GAT\-1 inhibitor used in the therapy of refractory epilepsy. One of the reasons for the failure to design new inhibitors with the desired activity, selectivity, and physicochemical properties is the lack of knowledge about the exact structure of particular types of GABA and glycine transporters, especially about their binding sites and mode of interaction with ligands. Therefore, the overall objective of this doctoral dissertation was to determine the exact structure of the transporters for gamm"]

Number of results: 1